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The guanabenz derivative Sephin1 has recently been proposed to increase the levels
of translation initiation factor 2 (eIF2α) phosphorylation by inhibiting dephosphorylation
by the protein phosphatase 1—GADD34 (PPP1R15A) complex. As phosphorylation of
eIF2α by protein kinase R (PKR) is a prominent cellular antiviral pathway, we evaluated the
consequences of Sephin1 treatment on virus replication. Our results provide evidence
that Sephin1 downregulates replication of human respiratory syncytial virus, measles
virus, human adenovirus 5 virus, human enterovirus D68, human cytomegalovirus,
and rabbit myxoma virus. However, Sephin1 proved to be inactive against influenza
virus, as well as against Japanese encephalitis virus. Sephin1 increased the levels of
phosphorylated eIF2α in cells exposed to a PKR agonist. By contrast, in virus-infected
cells, the levels of phosphorylated eIF2α did not always correlate with the inhibition of
virus replication by Sephin1. This work identifies Sephin1 as an antiviral molecule in cell
culture against RNA, as well as DNA viruses belonging to phylogenetically distant families.
Keywords: PKR, GADD34, PPP1R15A, virus, antiviral, eIF2α, host, broad-spectrum
INTRODUCTION
Most clinically available antiviral drugs act by directly targeting viral components to inhibit a
critical step in the viral life cycle, such as entry, replication, or viral egress (1). These molecules
have several advantages, as they can be very potent inhibitors and should have minor side effects
because they are, in theory, virus specific. However, viruses evolve constantly and the selective
pressure of the treatment can give rise to mutants that are resistant to these drugs. This is illustrated
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for example by the emergence of influenza virus strains resistant
to viral neuraminidase inhibitors (2).
By contrast, antiviral molecules targeting host functions that
are necessary for the virus life cycle are less likely to lead to
the emergence of resistant viral mutants (3). Moreover, broad-
spectrum antiviral molecules can be developed if the targeted
host cell function regulates the replication of a wide range of
viruses. Numerous host factors have been identified as required
for viral replication through whole-genome genetic screens,
providing impetus to develop antiviral molecules targeting
these host factors (4). The numerous pathways experimentally
identified as potential targets for antiviral therapy include
viral entry or egress, viral assembly, viral protein synthesis
or maturation, and the immune response against viruses (3,
5, 6). Currently, approved drugs targeting the host include
the widely used type I interferons, which boost the antiviral
innate immune response, ribavirin, which modulates the pool of
intracellular nucleosides and is reported to modulate the innate
immune response, and finally maraviroc, inhibiting human
immunodeficiency virus entry by targeting C-C chemokine
receptor type 5 (CCR5) (1). In an effort to limit toxicity, it is
necessary to target a host cell function that is not crucial to the
cell physiology and/or that is more specific to infected cells.
The phosphorylation of serine 51 of the α subunit of
eukaryotic translation initiation factor 2 (eIF2α) inhibits
initiation of protein translation in response to various cellular
stresses (7). Four protein kinases have been shown to specifically
phosphorylate eIF2α. The protein kinase RNA-like endoplasmic
reticulum kinase (PERK) phosphorylates eIF2α in response
to endoplasmic reticulum stress, due to the accumulation
of unfolded proteins in the endoplasmic reticulum or to
perturbations of the endoplasmic reticulum membrane lipid
composition (8, 9). The haem-regulated inhibitor kinase (HRI)
phosphorylates eIF2α in response to iron deficiency and has
been demonstrated to regulate the differentiation of red blood
cells (10). The general control non-derepressible-2 (GCN2)
phosphorylates eIF2α in response to amino-acid deficiency (11).
Finally, the interferon-induced double-stranded RNA-activated
protein kinase (PKR) phosphorylates eIF2α in response to the
accumulation of viral RNA harboring a double-stranded or
other nucleic acids secondary structures produced during viral
replication (12). Increased eIF2α phosphorylation attenuates
translation of most mRNAs and is a physiological response to
adapt to the various cellular stresses described above. Activation
of PKR is for example an antiviral response aiming at reducing
the translation of viral proteins in infected cells. The importance
of PKR in antiviral defense is illustrated by the broad-array of
viral countermeasures selected during evolution to inhibit PKR
activation or eIF2α phosphorylation (12). It should however be
noted that increased eIF2α phosphorylation seems to benefit
to some viruses, including viruses belonging the Togaviridae
family (13), Reoviridae family (14), and hepatitis C virus
(15), most likely because translation of their mRNAs relies
on secondary structures from which initiation can proceed
even in the presence of high levels of eIF2α phosphorylation
(12). As a consequence, developing means to increase eIF2α
phosphorylation could be an antiviral intervention only for
viruses whose mRNA translation is inhibited by increased eIF2α
phosphorylation.
Dephosphorylation of eIF2α allows the cell to resume
initiation of protein translation and is achieved by a binary
complex between the catalytic phosphatase subunit PP1 and a
regulatory subunit composed of either GADD34 (or PPP1R15A)
(16) or CReP (or PPP1R15B) (17). The regulatory subunits
GADD34 and CReP target the phosphatase PP1 specifically
to the phosphorylated eIF2α substrate. CReP is constitutively
expressed. By contrast, GADD34 expression is induced by eIF2α
phosphorylation and therefore should be specifically expressed
in stressed cells. GADD34 thus provides a negative feedback on
eIF2α phosphorylation (8).
The guanabenz derivative Sephin1 was shown to increase
eIF2α phosphorylation in cells stimulated with drugs causing
PERK activation via the accumulation of unfolded proteins in the
endoplasmic reticulum lumen (18). Sephin1 was described as a
specific inhibitor of GADD34, although the identity of its target is
currently subject of debate [see section Discussion and (19–21)].
We reasoned that inhibition of GADD34 could have antiviral
effects by potentiating eIF2α phosphorylation in infected cells.
Moreover, given that GADD34 is induced in cells with increased
eIF2α phosphorylation, a GADD34 inhibitor should specifically
act in stressed cells, such as infected cells, thus enhancing
drug selectivity.
In the current work, we provide evidence that Sephin1
exhibited antiviral effects against specific viruses belonging to
various viral families. In addition, Sephin1 increased eIF2α
phosphorylation in response to activators of PKR, suggesting
that Sephin1 may act by increasing eIF2α phosphorylation in
virus-infected cells.
MATERIALS AND METHODS
Reagents and Cellular Treatments
Cells were treated for 16 h with 2.5µg/ml tunicamycin (Sigma,
USA) or with 1µg/ml of intracellularly delivered Poly(I:C)
(HMW)/LyoVec (Invivogen, France). Sephin1 was purchased
from Tocris (United-Kingdom) or synthesized according to the
protocol described in Das et al. (18). Purity was verified by
nuclear magnetic resonance. Sodium arsenite (Sigma, USA) was
added to cells in culture at a final concentration of 500µM for
1 h before lysis. Cells were treated for 24 h with 1,000 U/ml of
bacterially produced recombinant human interferon α A (PBL
assay science, USA).
Cells and Viruses
Human HEK293, HEK293T, human ARPE-19, and rabbit RK13
cells were grown at 37◦C in DMEM containing glutamate
supplemented with 10% FBS, 1x penicillin-streptomycin. Human
HEp-2 cells were grown at 37◦C in MEM containing glutamate
supplemented with 10% FBS, 1x Penicillin-Streptomycin. Wild-
type mouse embryonic fibroblasts (MEF WT) and MEF in
which the endogenous eIF2α gene has been genetically replaced
by a nonphosphorylable (S51A) allele (MEF S51A) have been
described previously and were kindly provided by David Ron,
University of Cambridge, United Kingdom (22, 23). Human
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respiratory syncytial virus (hRSV), derived from the strain
Long, genetically modified to express firefly luciferase or the
fluorescent protein mCherry were previously described and used
to infect HEp-2 cells (24). Enterovirus D68, kindly provided by
Caroline Tapparel, Université de Genève, Switzerland (25), was
used to infect human RD cells cultured at 33◦C, as previously
described (26). Human adenovirus serotype 5 (hAdV), belonging
to serotype 5, genetically modified to express the bacterial
partitioning system-based AnchOR3 was used to infect human
HEK cells, as recently described (27). Measles virus strain
Schwartz genetically modified to express the firefly luciferase (28)
was used to infect human HEKT cells, as previously described
(29). Myxoma virus strain T1 was used to infect RK13 cells
as previously described (30). Human cytomegalovirus (hCMV)
derived from the TB40/E strain and genetically modified to
express the bacterial partitioning system-based AnchOR3 was
used to infect human ARPE-19 cells, as recently described (31).
The AnchOR3 system is distributed by NeoVirTech SAS, France
and is available upon request. Influenza A/Puerto Rico/8/1934
(H1N1) and A/turkey/Italy/977/1999(H7N1) were used to infect
A549 or MDCK cells, as previously described (32, 33). Japanese
encephalitis virus genotype 3 strain Nakayama (34) was used
to infect HEK293T cells. Briefly, HEK293T cells were infected
with JEV at a MOI of 0.01 for 48 h and JEV RNAs in cell
supernatants were quantified by real-time RT-PCR as described
in Yang et al. (35). Theiler’s murine encephalomyelitis virus
(TMEV) genetically modified to express a mutant L protein
and the fluorescent protein Cherry (36) was used to infect
MEF WT and MEF S51A. Cellular viability was measured with
Vita-Blue Cell Viability Reagent (Biomake) according to the
manufacturer’s protocol. This assay is based on a fluorescent
dehydrogenase enzymes substrate, which correlates with cellular
metabolic activity.
Western-Blot Analyses
Cells were lysed as previously described (37) and used for
western-blot analyses. Phosphorylated eIF2α was detected with a
polyclonal rabbit antibody (ab32157, Abcam, United-Kingdom)
or (44-728G, ThermoFischer Scientific, USA). Total eIF2α was
detected with a polyclonal rabbit antibody (Proteintech, USA).
Quantification of Virus Replication
Myxoma virus titers were determined by standard plaque assay
on RK13 cells, as described in Camus-Bouclainville et al. (30).
Enterovirus D68 and influenza virus titers were determined
by the tissue culture infectious dose 50 (TCID50) method, as
described in Soubies et al. (38). We measured replication of
luciferase expressing virus 24 h post-infection by lysing cells and
measuring light emission on a Clariostar (BMG Labtech) plate
reader using the Luciferase assay System kit (Promega) according
to the manufacturer’s instructions. We measured replication of
TMEV expressing the fluorescent protein Cherry by measuring
fluorescence using a Clariostar (BMG Labtech) plate reader.
hRSV expressing Cherry was detected in paraformaldehyde
fixed HEp-2 cells by immunofluorescence and imaged using a
confocal microscope. Replication of hAdV and hCMV expressing
AnchOR3 protein was quantified by measuring GFP foci using
automated microscopy, as described in Komatsu et al. (27) and
Mariamé et al. (31).
Rabbit Infections and Treatments
Rabbit infections and treatments were described in a protocol
approved by the Ethical committee Science et Santé Animale
(SSA 115) and the French Ministry of Research (protocol
reference number 2015112009419390). Rabbits were infected by
injection of 50 plaque-forming units of myxoma virus wild-
type strain in the dermis of the right ear. The myxoma virus
wild-type strain LH 3082 used for the in vivo infection was
isolated in 2008 from the eyelid of a rabbit found dead in a
farm in the South West of France. Sephin1 was solubilized in
DMSO at a concentration of 1 mg/ml and further diluted in
pineapple juice to administer either at 5 mg/kg (first experience),
or 100 mg/kg (second experiment) by a single daily oral
administration. Control animals received equivalent volumes of
DMSO in pineapple juice. Animals were monitored daily for
clinical signs and conjonctival swabs were performed at the
indicated days post-infection to monitor for virus replication as
recommended (39).
RESULTS
Consequences of Sephin1 Treatment on
eIF2α Phosphorylation in Cells Stimulated
With Known Stimulators of eIF2α Kinases
To determine the levels of eIF2α phosphorylation, we performed
western-blot analysis using antibodies against phosphorylated
eIF2α and against total eIF2α. In order to verify the specificity
of these antibodies, we treated cells with sodium arsenite, a well-
known potent inducer of eIF2α phosphorylation that mainly
activates HRI (40). High levels of phosphorylated eIF2α were
detected in sodium arsenite treated cells (Figure 1A, lanes 7),
demonstrating the specificity of these antibodies and the position
of the band corresponding to phosphorylated eIF2α, indicated
with an asterisk. To evaluate the consequences of Sephin1
treatment on eIF2α phosphorylation, we exposed HEKT cells
to the glycosylation inhibitor, tunicamycin, a known inducer
of ER stress causing the accumulation of unfolded proteins
in the ER. The accumulation of unfolded proteins in the
ER leads to the activation of PERK, which phosphorylates
eIF2α. As expected, eIF2α phosphorylation was increased in
cells treated with tunicamycin (Figure 1A, lanes 1 vs. 5). Co-
treatment with Sephin1 increased tunicamycin-induced eIF2α
phosphorylation (Figure 1A, lanes 5 vs. 6), in agreement with
previously published results (18). We next evaluated if Sephin1
could also potentiate eIF2α phosphorylation in the context of
viral infections by stimulating cells with intracellularly delivered
Poly(I:C), a synthetic RNA mimicking viral RNA and known to
stimulate PKR (41). Poly(I:C) induced eIF2α phosphorylation
(Figure 1A, lanes 1 vs. 3), which was further increased in cells
treated simultaneously with Sephin1 (Figure 1A, lanes 3 vs. 4).
Upon interferon α-pretreatment, which is known to upregulate
PKR expression, we observed increased eIF2α phosphorylation
in Poly(I:C)-treated HEK293T cells (Supplementary Figure 1,
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FIGURE 1 | Consequences of Sephin1 treatment on eIF2α phosphorylation.
(A) HEK293T cells were either left untreated (NT), treated for 16 h with
intracellularly delivered poly(I:C), which stimulates PKR or with tunicamycin
(Tun), which stimulates PERK, in the presence or absence of 50µM Sephin1.
The asterisk indicates the position of phosphorylated eIF2α, as revealed in
cells stimulated with sodium arsenite (As), a potent inducer of eIF2α
phosphorylation. (B) RD cells and (C) HEp-2 cells were either left untreated
(NT) or treated for 16 h with intracellularly delivered poly(I:C), in the presence or
absence of 50µM Sephin1. The mean fold increase of the phosphorylated
eIF2α phosphorylation/total eIF2α ratio normalized to non-treated cells
calculated from three independent experiments is shown below the
photographs.
lanes 3 vs. 7). Simultaneous treatment with Sephin1 further
increased eIF2α phosphorylation in Poly(I:C)-treated cells
(Supplementary Figure 1, lanes 7 vs. 8). Sephin1 treatment also
increased eIF2α phosphorylation in RD cells (Figure 1B) and
in HEp-2 cells (Figure 1C) treated overnight with intracellularly
delivered Poly(I:C). Altogether, these results suggest that Sephin1
could boost PKR-mediated eIF2α phosphorylation, possibly by
inhibiting GADD34-mediated dephosphorylation of eIF2α.
Evaluation of the Antiviral Properties of
Sephin1 Against RNA Viruses
Human respiratory syncytial virus (hRSV) is a negative strand
RNA virus belonging to the Pneumoviridae family. hRSV is a
common cause of acute lower respiratory disease in infants and
young children. Current antiviral therapies against hRSV are
limited to an expensive humanized monoclonal antibody used
as a prophylactic treatment and to ribavirin, which has limited
efficacy and relatively high toxicity (42). There is therefore a
need to develop new antiviral therapies. In order to test if
Sephin1 was able to inhibit hRSV replication, we infected HEp-
2 cells with a genetically engineered hRSV expressing the Firefly
luciferase, used to quantify virus replication (24). Following virus
adsorption for 1 h, cells were treated with increasing doses of
Sephin1. Measurement of luciferase activity 24 h post-infection
revealed a dose dependent inhibition of hRSV replication by
Sephin1 (Figure 2A). A 30-fold inhibition of replication was
observed when Sephin1 was used at 50µM, which is the
highest dose used in the experiments. Cellular viability was
measured with a fluorescent dehydrogenase enzymes substrate,
which reveals cellular metabolic activity. Cellular viability
did not decrease significantly following Sephin1 treatment
for 24 h and remained above 80% in HEp-2 cells treated
with 50µM Sephin1 (Figure 2B). Fluorescence and bright-field
microscopic analysis of HEp-2 cells infected with a genetically
engineered hRSV expressing the fluorescent protein Cherry
(24) confirmed that treatment with 50µM Sephin1 for 24 h
led to a significant reduction of virus replication and was not
associated with significant changes in cellular morphology or
density (Figure 2C).
We further documented the antiviral spectrum of Sephin1 by
testing its antiviral potential against measles virus. Measles virus
is a negative strand RNA virus belonging to the Paramyxoviridae
family currently causing large outbreaks due to suboptimal
vaccination coverage in many countries (43). To evaluate the
antiviral properties of Sephin1 against measles virus, we infected
human HEK293T cells with a genetically engineered measles
virus expressing the Firefly luciferase (28). Following virus
adsorption for 1 h, cells were treated with increasing doses of
Sephin1. Measurement of luciferase activity 24 h post-infection
revealed a dose dependent inhibition of measles virus replication
in HEK293T cells by Sephin1 (Figure 3A). A 10-fold inhibition
of replication was observed when Sephin1 was used at 40µM,
which is the highest dose used in these experiments. Cellular
viability remained above 75% in HEK293T cells treated for 24 h
with 40µM Sephin1 (Figure 3B).
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FIGURE 2 | Evaluation of the antiviral properties of Sephin1 against hRSV. (A) HEp-2 cells were infected with a recombinant strain of hRSV expressing luciferase and
incubated with increasing doses of Sephin1 or DMSO alone. After 24 h, luciferase expression was determined. (B) Viability of HEp-2 cells incubated with increasing
doses of Sephin1 or DMSO alone was determined after 24 h of incubation using the cellular viability assay Vita-Blue. (C) HEp-2 cells were infected with a recombinant
strain of hRSV expressing mCherry and incubated with increasing doses of Sephin1 or DMSO alone. After 24 h, cells were fixed and imaged using a confocal
microscope. Data represent mean ± SEM from representative experiments, repeated at least three times. *p < 0.05, **p < 0.01 by one-way analysis of variance,
followed by Bonferroni comparison test comparing the Sephin1-treated group at the indicated concentration to the vehicle-treated control group.
FIGURE 3 | Evaluation of the antiviral properties of Sephin1 against measles virus. (A) HEK293T cells were infected with a recombinant strain of measles virus
expressing luciferase and incubated with increasing doses of Sephin1 or DMSO alone. After 24 h, luciferase expression was determined. Data represent mean values
from a representative experiment, repeated at least three times. (B) Viability of HEK293T cells incubated with increasing doses of Sephin1 or DMSO alone was
determined after 24 h incubation using the cellular viability assay Vita-Blue. Data represent mean ± SEM from representative experiments, repeated at least three
times. ***p < 0.001 by one-way analysis of variance, followed by Bonferroni comparison test comparing the Sephin1-treated groups at the indicated concentrations to
the vehicle-treated control group.
We next tested the antiviral properties of Sephin1 against
enterovirus D68. Enterovirus D68 is a positive strand RNA
virus belonging to the Picornaviridae family and causing
upper respiratory tract infections in children (44). To mimic
physiological temperatures found in the human upper tract,
we infected human RD cells grown at 33◦C with enterovirus
D68 (26). Cells were infected at a low MOI to allow multiple
cycles of infection. Following virus adsorption for 1 h, cells
were treated with 50µM Sephin1 and supernatants collected
at the indicated time post-infection to quantify viral load by
standard tissue culture infectious dose 50 (TCID50) method.
Treatment with 50µM Sephin1 caused a more than 10-fold
reduction of enterovirus ED68 titers (Figure 4A). Inhibition of
enterovirus ED68 was readily detected at 24 h post-infection and
persisted throughout the experiment up to 72 h post-infection,
even though Sephin1 was added via a single treatment in the
culture medium at 1 h post-infection. RD cells viability did
not decrease significantly following 50µM Sephin1 treatment
for 24 h and remained above 90% (Figure 4B), consistent with
cellular viability results observed in Sephin1-treated HEp-2 cells
and HEK293T cells.
We further tested the antiviral potential of Sephin1 against
influenza A virus. We infected human A549 cells with
the influenza A/Puerto Rico/8/1934 (H1N1) strain at a low
multiplicity of infection. Following 1 h adsorption, A549 cells
were treated with 50µM Sephin1 or control cells treated with
vehicle only. Viral titers in the supernatants were determined by
standard plaque assay. We did not observe any inhibitory effect
of Sephin1 on influenza virus replication (Figure 5). Similar
results were obtained when experiments were performed on the
canine MDCK cell line or when experiments were performed
with the avian influenza A/turkey/Italy/977/1999(H7N1) virus
strain (data not shown).
To assess the antiviral potential of Sephin1 against a virus
belonging to the Flaviviridae family, we infected HEK293T cells
with Japanese encephalitis virus. Sephin 1 had no effect on
the replication of Japanese encephalitis virus, as determined by
quantifying viral genomes in the supernatants by quantitative
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FIGURE 4 | Evaluation of the antiviral properties of Sephin1 against enterovirus ED68. (A) RD cells were infected with enterovirus ED68 and incubated at 33◦C in the
presence of 50µM Sephin1 or DMSO alone (control). Viral titers were determined from supernatants harvested at the indicated times post-infection. (B) Viability of RD
cells incubated with increasing doses of Sephin1 or DMSO alone was determined after 24 h of incubation using the cellular viability assay Vita-Blue. Data represent
mean ± SEM from representative experiments, repeated at least three times. *p < 0.05 by one-way analysis of variance, followed by Bonferroni comparison test
comparing the Sephin1-treated groups at the indicated concentrations to the vehicle-treated control group.
FIGURE 5 | Evaluation of the antiviral properties of Sephin1 against influenza
virus. A549 cells were infected with influenza A/Puerto Rico/8/1934 (H1N1)
strain and incubated in the presence of 50µM Sephin1 or DMSO alone
(control). Viral titers were determined from supernatants harvested at the
indicated times post-infection. Data represent mean ± SEM from a
representative experiment, repeated at least three times.
RT-PCR (Figure 6). We thus identified viruses that are not
inhibited by Sephin1, demonstrating that although Sephin1
has a broad antiviral spectrum, it is not active against
all viruses.
Evaluation of the Antiviral Properties of
Sephin1 Against DNA Viruses
In order to test if Sephin1 could inhibit phylogenetically
distant viruses, we analyzed its antiviral potential against
human Adenovirus (hAdV), a DNA virus belonging to the
Adenoviridae family causing respiratory tract infections in
humans. A genetically modified hAdV expressing the bacterial
partitioning system-based AnchOR3 was used to infect HEK293
cells. The AnchOR3 system allows for the real-time detection
of viral DNA replication in living cells through the detection of
GFP foci and is therefore used to monitor DNA virus replication
FIGURE 6 | Evaluation of the antiviral properties of Sephin1 against Japanese
encephalitis virus. HEK293T cells were infected with Japanese encephalitis
virus and incubated in the presence of 50µM Sephin1 or DMSO alone
(control). Viral titers were determined by quantitative RT-PCR from
supernatants harvested at the indicated times post-infection. Data represent
mean ± SEM from a representative experiment, repeated at least three times.
in real-time by fluorescent microscopy (27). Cells were treated
with increasing doses of Sephin1 or vehicle only and infected
immediately with AnchOR3 hAdV. Measurement of GFP
fluorescent foci by automated microscopy 24 h post-infection
revealed a dose dependent inhibition of hAdV replication by
Sephin1 (Figure 7A). A four-fold inhibition of replication was
observed when Sephin1 was used at 50µM, which is the
highest dose used in the experiments. Cellular viability did
not decrease significantly following Sephin1 treatment for 24 h
and remained above 80% in HEK293 cells treated with 50µM
Sephin1 (Figure 7B).
We next analyzed the antiviral potential of Sephin1 against
myxoma virus, a DNA virus of the Poxviridae family,
which contains pathogens of major importance in human
and veterinary medicine. Myxoma virus is responsible for
Myxomatosis in European rabbits, a disease of medical
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FIGURE 7 | Evaluation of the antiviral properties of Sephin1 against human Adenovirus. (A) HEK293 cells were infected with a recombinant strain of hAdV expressing
ANCHOR3 and incubated with increasing doses of Sephin1 or DMSO alone. After 24 h, virus replication was determined by automated counting of GFP foci. (B)
Viability of HEK293 cells incubated with increasing doses of Sephin1 or DMSO alone was determined after 24 h incubation using the cellular viability assay Vita-Blue.
Data represent mean ± SEM from representative experiments, repeated at least three times. ***p < 0.001 by one-way analysis of variance, followed by Bonferroni
comparison test comparing the Sephin1-treated groups at the indicated concentrations to the vehicle-treated control group.
importance in veterinary medicine, worsened due to the
emergence of strains causing respiratory diseases in rabbits
(39). Following myxoma virus adsorption for 1 h, rabbit
RK13 cells were treated with 50µM Sephin1. Cells and
supernatants were harvested at 24, 72, and 120 h post-infection
and subjected to three freeze-thaw cycles to detect free
viral particles, as well as cell-associated virus particles (30).
Virus titration by standard plaque-assay revealed that Sephin1
significantly inhibited myxoma virus replication (Figure 8A).
Cellular viability did not decrease significantly following Sephin1
treatment of RK13 cells for 24 h (Figure 8B).
Finally, we evaluated the antiviral of Sephin1 against human
cytomegalovirus (hCMV), a DNA virus belonging to the
Herpesviridae family. hCMV is widespread in the human
population and causes severe diseases following congenital
infection. A genetically modified hCMV expressing the
AnchOR3 system to detect viral DNA replication by the
accumulation of GFP foci was used to infect the human retinal
pigment cell line ARPE-19 (31). Sephin1 had a dose-dependent
inhibitory effect on hCMV replication in the human ARPE-19
cell line, reaching a five-fold inhibition at 50µM (Figure 9A).
At this dose Sephin1 caused a 40% reduction in cellular viability,
indicating that Sephin1 is associated with moderate toxicity
at 50µM in the ARPE-19 cell line (Figure 9B). Altogether
these results provide evidence that Sephin1 has antiviral
activity against respiratory viruses belonging to phylogenetically
distant families.
Evaluation of the Contribution of eIF2α
Phosphorylation to the Antiviral Effects of
Sephin1
To test if the antiviral effect of Sephin1 correlated with increased
eIF2α phosphorylation, we performed western-blot analyses of
virus-infected cells. eIF2α phosphorylation was increased in
cells infected with hRSV (Figure 10A, compare lanes 1 and 3).
However, treatment with 50µM Sephin1 did not increase eIF2α
phosphorylation in hRSV-infected cells (Figure 10A, compare
lanes 3 and 4). eIF2α phosphorylation was not increased in
cells infected with measles virus (Figure 10B, compare lanes
1 and 3) or in cells infected with myxoma virus (Figure 10C,
compare lanes 1 and 3), even when cells were treated with
50µM Sephin1 (Figures 10B,C, compare lanes 3 and 4).
Thus, the antiviral activity of Sephin1 does not correlate with
increased eIF2α phosphorylation, raising the possibility that
some antiviral effects of Sephin1 could be independent of
eIF2α phosphorylation.
To test if Sephin1 could inhibit virus replication
independently of eIF2α phosphorylation, we compared wild-
type mouse embryonic fibroblasts (MEF WT) and mouse
embryonic in which the endogenous eIF2α gene has been
genetically replaced by a nonphosphorylable (S51A) allele
(MEF S51A) (22). These cells were infected with Theiler’s
murine encephalomyelitis virus (TMEV), a positive strand
RNA virus belonging to the Picornaviridae family. We used
a genetically modified virus, which has a deleted L protein,
rendering the virus highly susceptible to the antiviral effects
of PKR and expressing the fluorescent protein Cherry, used as
a reporter to quantify virus replication (36). Following virus
adsorption for 1 h, cells were either treated with vehicle
only or treated with 50µM Sephin1. Virus replication
was evaluated by measuring Cherry fluorescence using
a fluorescent microplate reader. Sephin1 reduced Cherry
fluorescence in MEF WT cells, indicating that it inhibited
TMEV-Cherry replication in MEF WT cells (Figure 10D).
Surprisingly, Cherry fluorescence was higher in Sephin1-
treated MEF S51A cells compared to non-treated S51A
cells, indicating that Sephin1 treatment increased TMEV
replication in cells expressing nonphosphorylable eIF2α
(Figure 10E). It is currently unclear how Sephin1 could increase
TMEV replication in cells expressing nonphosphorylable
eIF2α. This result nevertheless demonstrates that eIF2α
phosphorylation is required for the antiviral effects of Sephin1
against TMEV.
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FIGURE 8 | Evaluation of the antiviral properties of Sephin1 against myxoma virus. (A) RK13 cells were infected with myxoma virus and incubated in the presence of
50µM Sephin1 or DMSO alone (control). Viral titers were determined from crude lysates harvested at the indicated times post-infection. (B) Viability of RK13 cells
incubated with increasing doses of Sephin1 or DMSO alone was determined after 24 h incubation using the cellular viability assay Vita-Blue. Data represent mean ±
SEM from representative experiments, repeated at least three times. **p < 0.001, ***p < 0.001 by one-way analysis of variance, followed by Bonferroni comparison
test comparing the Sephin1-treated groups at the indicated concentrations to the vehicle-treated control group.
FIGURE 9 | Evaluation of the antiviral properties of Sephin1 against human cytomegalovirus. (A) ARPE-19 cells were infected with a recombinant strain of hCMV
expressing ANCHOR3 and incubated with increasing doses of Sephin1 or DMSO alone. After 72 h, virus replication was determined by automated counting of GFP
foci. (B) Viability of ARPE-19 cells incubated with increasing doses of Sephin1 or DMSO alone was determined after 72 h incubation using the cellular viability assay
Vita-Blue. Data represent mean ± SEM from representative experiments, repeated at least three times. ***p < 0.001 by one-way analysis of variance, followed by
Bonferroni comparison test comparing the Sephin1-treated groups at the indicated concentrations to the vehicle-treated control group.
Sephin1 Is Showing Some Antiviral Effect
in vivo, Which Is However Limited by Toxic
Side Effects
In order to evaluate if Sephin1 could exert antiviral activity
in vivo, we evaluated its therapeutic potential in European rabbits
infected with myxoma virus. European rabbits are the natural
hosts of myxoma virus. Rabbits were inoculated with 50 plaque-
forming units of myxoma virus strain LH 3082 by intradermal
inoculation in the right ear lobe. Sephin1 was administered
by oral gavage once daily at a dose of 5 mg/kg. Treatment
with Sephin1 began straight after virus inoculation. Control
rabbits were treated similarly with vehicle. Except for two rabbits
in the control group and one rabbit in the Sephin1-treated
group, no other infected rabbits developed clinical signs of
myxomatosis over the period of observation. Sephin1 appeared
to be well-tolerated at a daily dose of 5mg/kg, as Sephin1-treated
rabbits were clinically indistinguishable from the control rabbits.
Conjonctival swabs were performed on day 0, 5, 9, and 11 to
monitor for virus replication by q-PCR (Figure 11). Levels of
viral DNA increased in non-treated control animals over the
observation period, indicating efficient virus replication in the
rabbits. The levels of virus replication were much higher for
the three rabbits showing clinical signs, indicated by arrows
in Figure 11. We observed a significant reduction in virus
replication at day 11 post-infection in the Sephin1-treated group
compared to the control group, demonstrating that Sephin1
can exert an antiviral activity in vivo. However, the antiviral
activity of Sephin1 given orally at 5 mg/kg daily was modest.
We therefore repeated the experiment in order to administer
Sephin1 at a higher dosage. In this second in vivo experiment,
rabbits were infected as previously. Sephin1 was administered
by oral gavage once daily at a dose of 100 mg/kg beginning
straight after inoculation.When used at 100 mg/kg, acute toxicity
was observed as soon as 2 days post-infection in the Sephin1
treated rabbits, which developed anorexia and presented ruﬄed
fur. For ethical reasons, in compliance with the guidelines from
the animal care and use committee, we euthanized the animals
and terminated the experiment. Altogether these results suggest
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FIGURE 10 | Evaluation of the contribution of eIF2α phosphorylation to the antiviral effects of Sephin1. Cells were either left non-infected (NI) or infected with the
indicated viruses, in the presence or absence of 50µM Sephin1. Sodium arsenite (As), a potent inducer of eIF2α phosphorylation, was used as a positive control for
detection of eIF2α phosphorylation by western-blot. (A) Analysis of eIF2α phosphorylation in HEp-2 cells infected with hRSV. (B) Analysis of eIF2α phosphorylation in
HEK293T cells infected with measles virus. (C) Analysis of eIF2α phosphorylation in RK13 cells infected with myxoma virus. (D) Consequences of Sephin1 treatment
on TMEV replication in WT mouse embryonic fibroblasts (MEF WT). (E) Consequences of Sephin1 treatment on TMEV replication in mouse embryonic fibroblasts
expressing a non-phosphorylable (S51A) allele of eIF2α (MEF S51A). TMEV replication was determined by measuring mCherry fluorescence. Data represent mean ±
SEM from representative experiments, repeated at least three times.
that although Sephin1 has some antiviral activity in vivo at 5
mg/kg, increasing the dosage to reach higher concentrations and
possibly better antiviral activity is currently not possible due to
the existence of major side effects.
DISCUSSION
Negative strand RNA viruses, positive strand RNA viruses, as
well as DNA viruses were inhibited by Sephin1 treatment in cell
culture. Our results thus provide evidence that Sephin1 treatment
has antiviral properties against a broad range of viruses belonging
to phylogenetically distant viral families. A four to 100-fold
inhibition of viral replication was obtained when Sephin1 was
used at 50µM. At this dose, cellular viability remained above
75% in all cell lines tested, with the exception of ARPE-19 cells,
which had a 40% decrease in viability. This result demonstrates
that, although the molecule had to be used at a high dose to reach
a significant antiviral effect, inhibition of virus replication could
not be attributable to alterations in cellular viability.
Secondary structures found in the RNA of some positive
strand RNA viruses, such as viruses belonging to the Togaviridae
family, Reoviridae family and hepatitis C virus, allow translation
of these RNAs to proceed normally, or in some cases better,
in the presence of high levels of eIF2α phosphorylation (12).
It is therefore expected that Sephin1 would have no antiviral
effect against these viruses. In the case of influenza virus, the
lack of antiviral activity of Sephin1 might be attributable to the
tight inhibition of PKR activation by the viral protein NS1 (45).
This inhibition is mediated by the binding of NS1 to PKR (46).
Influenza A viruses with mutant NS1 proteins unable to bind
to PKR are highly attenuated in wild-type mice, but replicate
to high levels in PKR deficient mice (46). By contrast, wild-type
influenza viruses replicate to similar levels in wild-type mice and
in PKR deficient mice (46, 47). These observations suggest that
PKR is an important antiviral pathway against influenza viruses,
which is very efficiently counteracted by wild-type NS1 protein.
The lack of activity of Sephin1 observed in cell culture may be
due to the absence of PKR activation and eIF2α phosphorylation
in influenza virus infected cells, as previously described (48).
Similarly, the lack of antiviral activity of Sephin1 against Japanese
encephalitis virus could be due to the tight inhibition of PKR
activation by the viral protein NS2A (49). In the absence of eIF2α
phosphorylation and consequent expression of GADD34, it is
anticipated that Sephin1 would have no effect.
GADD34 has been shown to stimulate type I interferon
production in response to the synthetic viral RNA analog
poly(I:C) and in response to infection with Chikungunya virus,
a member of the Togaviridae family (50). Activation of PKR
by poly(I:C) and in response to Chikungunya virus infection
leads to eIF2α phosphorylation, which inhibits initiation of
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FIGURE 11 | Evaluation of the antiviral potential of Sephin1 against myxoma
virus in vivo. Rabbits were inoculated with 50 plaque-forming units of myxoma
virus. Eight rabbits were treated with Sephin1 by oral gavage once daily at a
dose of 5 mg/kg. Seven rabbits were administered vehicle only. Myxoma virus
DNA was detected by q-PCR from conjonctival swabs performed at the
indicated days post-infection. Rabbits exhibiting clinical signs are indicated
with an arrow. *p < 0.05 by the two-tailed Mann–Whitney test.
protein translation, including translation of type I interferons.
GADD34 expression and subsequent dephosphorylation of eIF2α
resume initiation of protein translation and consequently allow
translation of type I interferons (50). Inhibition of GADD34 is
therefore a double-edged sword. On one hand, increased eIF2α
phosphorylation caused by inhibition of GADD34 can potentiate
the antiviral effects by causing a tighter inhibition of viral protein
translation. On the other hand, a prolonged increase of eIF2α
phosphorylation caused by inhibition of GADD34 can inhibit
the translation of host proteins involved in antiviral defense,
such as type I interferons and antiviral effector proteins. The
potential beneficial effects of GADD34 inhibition are difficult to
predict. For viruses, such as members of the Togaviridae, which
are able to translate their proteins in the presence of high levels
of eIF2α phosphorylation, inhibition of GADD34 will likely be
detrimental to the host because of a reduction in the translation of
host proteins involved in antiviral defense. For viruses, which are
unable to translate their proteins in the presence of high levels of
eIF2α phosphorylation, the consequences of GADD34 inhibition
on viral replication are to our knowledge not predictable, and
therefore most likely need to be experimentally tested.
Inhibition of myxoma virus and measles virus by Sephin1 was
not associated with increased levels of eIF2α phosphorylation.
We thus did not observe a strict correlation between the antiviral
effects of Sephin1 and eIF2α phosphorylation. One tentative
explanation is that viral inhibition leads to a reduction in the
levels of viral PKR activators in Sephin1-treated cells compared
to infected non-treated cells. However, these observations also
raise the possibility that Sephin1 does not act by targeting
GADD34-PP1 mediated dephosphorylation of eIF2α. Indeed,
contradicting the initial description (18) and follow-up work
(21), Sephin1 and its derivative guanabenz were recently shown
to lack any effect on GADD34-PP1 mediated dephosphorylation
of eIF2α (19, 20, 51). We cannot rule out that Sephin1 mediates
its effects independently of GADD34. However, we observed
increased phosphorylation of eIF2α in cells stimulated with the
PERK activator tunicamycin and in cells stimulated with the
PKR activator poly(I:C). Moreover, the lack of antiviral activity
of Sephin1 against Theiler’s murine encephalomyelitis virus
(TMEV) in MEF cells expressing a nonphosphorylable (S51A)
allele demonstrates that eIF2α phosphorylation is required for the
antiviral effects of Sephin1 against TMEV. Whether these effects
are due to a specific inhibition of GADD34 by Sephin1 remains
to be investigated.
We observed amodest antiviral effect of Sephin1 administered
by oral gavage once daily at a dose of 5 mg/kg against myxoma
virus in rabbits. At 5 mg/kg, no toxic side effects were detected
by clinical examination of the rabbits. However, when we
administered Sephin1 by oral gavage once daily at a dose of
100 mg/kg, major clinical signs were detected, indicating that
at this dosage Sephin1 caused acute toxicity. GADD34 knock-
out mice were viable and did not show any clinical signs under
normal breeding conditions (52). This finding suggests that the
toxic side effects of Sephin1 observed in rabbits are unlikely due
to inhibition of GADD34, but rather point to Sephin1-induced
alterations in physiology that are independent of GADD34.
Ongoing studies to identify the causes of toxicity could provide
information for the development of new treatment regimens,
including new formulations and modes of administration. In
addition, Sephin1 can be the scaffold of structure-activity
relationship studies to identify new variants with increased
efficiency or decreased in vivo toxicity, and thus exhibiting
an improved selectivity index to consider these new variants
as promising therapeutic antiviral candidates. In this chemical
series, this is already well exemplified by the development of
Sephin1 itself, which is derived from guanabenz to eliminate
some unwanted binding to the α2- adrenergic receptor (18).
The prominent role of the PKR eIF2α pathway in antiviral
defense is well-established. Direct stimulators of PKR will
stimulate eIF2α phosphorylation in all cells exposed to the
drug, therefore likely leading to unwanted side effects in
non-infected cells. By contrast, GADD34 expression is stress-
inducible and drugs targeting GADD34 should therefore be
active only in cells that have increased levels of eIF2α
phosphorylation, including virus-infected cells, thus increasing
selectivity. GADD34 inhibitors would most likely be most
effective in complement with other molecules, such as drugs
targeting viral PKR antagonists or drugs thought to affect viral
protein folding, such as nitazoxanide (53) or iminosugars (54),
which could potentiate PERK-mediated eIF2α phosphorylation
in infected cells.
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